Figure 2 from Kestenbaum et al, AJKD © National Kidney Foundation, showing associations of CHIP with 30% decline in eGFR among subgroups of interest.

Clonal hematopoiesis of indeterminate potential (CHIP), defined by the age-related ontogenesis of expanded leukemogenic variants indicative of a genetically distinct clonal leukocyte population, is associated with risk of hematologic malignancy and cardiovascular disease. In a recent study published in AJKD, Bryan Kestenbaum et al., tested the hypothesis that CHIP is associated with kidney function decline in the general population.

AJKDBlog’s Interviews Editor, Timothy Yau @Maximal_Change sat down with one of the researchers, Dr. Caitlyn Vlasschaert @DrFlashHeart, to discuss their findings.

If the embedded player above doesn’t work, please click here to watch the video interview. Special thanks to Dr. Vlasschaert for taking the time to talk with us!

To view Kestenbaum et al (OPEN ACCESS), please visit AJKD.org.

Title: Clonal Hematopoiesis of Indeterminate Potential and Kidney Function Decline in the General Population
Author: Bryan Kestenbaum, Alexander Bick, Caitlyn Vlasschaert, Michael Rauh, Matthew Lanktree, Nora Franceschini, Moore Shoemaker, Raymond Harris Jr., Bruce Psaty, Anna Köttgen, Pradeep Natarajan, and Cassianne Robinson-Cohen.
DOI: 10.1053/j.ajkd.2022.08.014